stockrowSepterna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.
- Revenue
- +22,375.6%
- EPS
- +48.2%
- Free cash flow
- −9.01%
Quarter to June 2026, against a year earlier
Follow SEPN
Alert me
Septerna, Inc. (SEPN) EV/Sales
As of 5 November 2026, Septerna, Inc. (SEPN) trades at a EV/Sales of 18.1×. Over the past ten years it has ranged from −276× (February 2025) to 654× (September 2025); the current reading is higher than 67% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 18.3× | — |
| FY2024 | −116× | — |
| FY2023 | −87.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 11.5× | 14.01% |
| Mar 2026 | 10.1× | (45.06%) |
| Dec 2025 | 18.3× | 12.40% |
| Sep 2025 | 16.3× | (91.55%) |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −1.3× |
| VERA Vera Therapeutics, Inc. compare | n/m |
| BHVN Biohaven Ltd. compare | 2.2× |
| AUPH Aurinia Pharmaceuticals Inc compare | 5.3× |
| VCEL Vericel Corporation compare | 7.6× |
| SEPN Septerna, Inc. | 18.1× |
| PVLA Palvella Therapeutics, Inc. compare | 48.1× |
| ZYME Zymeworks Inc. compare | 49.5× |
| IMNM Immunome, Inc. compare | 121× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on SEPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- The full statement